Stifel Nicolaus Trims Zentalis Pharmaceuticals (NASDAQ:ZNTL) Target Price to $10.00
Zentalis Pharmaceuticals (NASDAQ:ZNTL – Free Report) had its target price decreased by Stifel Nicolaus from $32.00 to $10.00 in a research report report published on Tuesday morning, Benzinga reports. Stifel Nicolaus currently has a buy rating on the stock. Several other research analysts have also weighed in on ZNTL. Wells Fargo & Company lowered Zentalis […]
More Stories
Raymond James Financial Inc. Makes New $478,000 Investment in TrueBlue, Inc. (NYSE:TBI)
Raymond James Financial Inc. bought a new position in TrueBlue, Inc. (NYSE:TBI – Free Report) during the fourth quarter, according...
National Research Co. (NASDAQ:NRC) Shares Sold by Barclays PLC
Barclays PLC lowered its stake in National Research Co. (NASDAQ:NRC – Free Report) by 35.0% during the fourth quarter, according...
Barclays PLC Buys New Stake in Protara Therapeutics, Inc. (NASDAQ:TARA)
Barclays PLC bought a new position in shares of Protara Therapeutics, Inc. (NASDAQ:TARA – Free Report) during the fourth quarter,...
Barclays PLC Buys 11,876 Shares of Eastman Kodak (NYSE:KODK)
Barclays PLC lifted its stake in shares of Eastman Kodak (NYSE:KODK – Free Report) by 15.0% in the fourth quarter,...
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Shares Bought by Barclays PLC
Barclays PLC grew its holdings in shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Free Report) by 9.6% in the 4th...
Barclays PLC Acquires 3,399 Shares of Community West Bancshares (NASDAQ:CWBC)
Barclays PLC increased its stake in shares of Community West Bancshares (NASDAQ:CWBC – Free Report) by 15.4% during the fourth...